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ISCOMATRIX™ adjuvant links 






• Introduction to saponins
• Overview of ISCOMATRIX® adjuvant
• Mechanism of action
Saponins as adjuvants
Structure of quillaia saponin
High-molecular weight glycosides 
consisting of a sugar moieties 
linked to a triterpene
Quillaia saponins
• Quillaia saponaria tree




• Food and beverages
• Mining
• Vaccines
History of saponin as a vaccine 
adjuvant
• 1926 – Crude saponins - adjuvant activity reported (Ramon)
• 1951 – veterinary vaccine (Espinet) 
• 1970s – Quil A (Dalsgaard)
• Complex and toxic
• 1982 – ISCOM (Morein)
• 1987 – QS21 (Kensil)
• 1989 – ISCOMATRIX (Morein)
• 1995 – ISCOPREP 703 (CSL)
• 2000’s – AS series (GSK), ISCOPREP saponin (CSL), 
GPI0100 (HB), AbISCO (Isconova), Posintro (Nordic)
ISCOM, ISCOMATRIX and ISCOPREP are trademarks of CSL, AbISCO is a trademark of Isconova, Posintro is a trademark of Nordic
Summary of saponin based adjuvants
Adjuvant 
Name
Company Saponin Human Studies Comments
ISCOM
ISCOMATRIX
CSL ISCOPREP Flu, HCV, HPV E6E7, 
cancer, others
Licensed to Merck, 
Pfizer, Abbott
QS21 Antigenics QS21 Alzheimers, cancer Licensed to GSK 















- Multiple veterinary  
Licenses
Crucell (flu)
POSintro Nordic QuilA - -
Issues with saponin based adjuvants
• Saponin alone
• Haemolytic activity        reactogenicity
• Alkaline breakdown unstable
• Solution        complex with cholesterol (+ lipid)













QS21 (II) Pfizer QS21 -
AS01 (III) GSK QS21, MPL Liposome
AS02 (III) GSK QS21, MPL Oil-in-water







Saponin complexes induce balanced 
immune responses
CD4+ and CD8+ T cell responses










IL-2        IL-10
Summary of quillaia saponins
• Long history as immunomodulators in 
vaccines (veterinary)
• Purified fractions required for human use
• Need to be complexed with cholesterol




• A saponin-based adjuvant capable of 
inducing significant humoral and cellular 







Key features of 
ISCOMATRIX™ adjuvant technology
• Broad immune responses
• Antibody and cellular (including CTL)
• Safe and well tolerated in humans
• Clinical experience with range of antigens
• Non-clinical safety/toxicology package
• Industrial scale manufacturing
• Regulatory acceptance
• Well defined and characterised
• Master File
• Strong IP portfolio
ISCOMATRIX™ adjuvant: Ag delivery and 
immunomodulatory capabilities
ISCOMATRIX™ adjuvant integrates innate 
and adaptive immunity for CTL induction
• Antigen delivery
• Enhances cross-presentation
• Exogenous Ag into MHC Class I pathway (CD8+ T cells)
• Prolonged presentation in draining lymph node
• Immunomodulation
• Cytokine and chemokine induction




Immature MoDC pulsed with Alexa488-
OVA + ISCOMATRIX™ adjuvant
T=10min
Ag alone
Ag + ISCOMATRIX® adjuvant
Monocytes







































• Rapidly traffics protein via early (EEA-1+) and late 
(LAMP-1+) endosomes
• Trans-locates protein into cytosol
• Translocation is pH-dependent





MHC class I cross-presentation
Ag + ISCOMATRIX™ adjuvant
Ag






ISCOMATRIX™ vaccines recruit DC into 
DLN and prolong MHC I presentation
CD11c-DipTox mice
CD11c promoter 
Diphtheria toxin (DT) receptor (GFP+) chimeric mice
Radio-resistant 
Langerhans cells
Radiosensitive bone marrow-derived Dendritic cells     
( diphtheria toxin (DT) receptor positive)
Diphtheria toxin
treatment 2-3days
Are DCs are required for induction of CD8+ T 
cell responses? 
Radio-resistant Langerhans cells are not required
CD8+ T cell responses induced by OVA-
ISCOMATRIX™ vaccine in mice depleted of 
DCs
Lopez-Bravo and Ardavin, Immunity, 2009
Which DC Population(s) Cross-present 
ISCOMATRIX™ Vaccines?
Migratory and CD8α+ DC cross present Ag 
in response to ISCOMATRIX™ vaccines in 
vivo
Ag presentation: Two waves of ISCOMATRIX™
vaccine presentation



























0 2 4 6 24 48 72
Cross presentation is rapid and persistent








• ISCOMATRIX™ adjuvant:  
• Accesses several human DCs populations
• Rapidly delivers Ag into cytosol for access to MHC 
class I pathway (in addition to class II)
• Allows processing by proteasome dependent and 
independent mechanisms




Rapid and transient induction of cytokines 




Windon RG et al, Vaccine 19 (2001) 572-578
Sheep cannulation study
Time (hours)
ISCOMATRIX™ Adjuvant induces rapid and 















































































































ISCOMATRIX™ Adjuvant does not 
activate TLR signaling pathways in vitro
human or mouse 
cell lines in vitro
Doherty, T. M. et al. J. Clin. Invest.: 114 (2004)
MyD88 and TRIF mediated TLR 
signalling cascades
ISCOMATRIX™ vaccine induced CD8+ T 
cell responses are MyD88 dependent
-/- -/-
38
DC activation and presentation is normal 




IMX=ISCOMATRIX™ adjuvant  
MyD88 is also required for IL-1 and IL-18 
receptor signaling
Nakanishi K et al., 2001
40





• Targets and conditions multiple DC populations in 
vivo
• Delivers proteins into cytosol for class I MHC 
presentation (intracellular depot??)
• Induction of T cell responses involves MyD88/IL-
18-dependent pathway (non-TLR) 
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